Cargando…

Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience

Breast cancer, in India, is the second commonest cancer in females. Receptor status with ER/PR/Her 2 is now routinely done in patients with invasive carcinoma. The tumour suppressor gene, p53, is also present in most breast cancers. Proteins produced by a mutated p53 gene, accumulate in the nucleus...

Descripción completa

Detalles Bibliográficos
Autores principales: Patnayak, Rashmi, Jena, Amitabh, Rukmangadha, Nandyala, Chowhan, Amit Kumar, Sambasivaiah, K., Phaneendra, Bobbit Venkatesh, Reddy, Mandyam Kumaraswamy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477374/
https://www.ncbi.nlm.nih.gov/pubmed/26157289
http://dx.doi.org/10.4103/0971-5851.158844
_version_ 1782377746345754624
author Patnayak, Rashmi
Jena, Amitabh
Rukmangadha, Nandyala
Chowhan, Amit Kumar
Sambasivaiah, K.
Phaneendra, Bobbit Venkatesh
Reddy, Mandyam Kumaraswamy
author_facet Patnayak, Rashmi
Jena, Amitabh
Rukmangadha, Nandyala
Chowhan, Amit Kumar
Sambasivaiah, K.
Phaneendra, Bobbit Venkatesh
Reddy, Mandyam Kumaraswamy
author_sort Patnayak, Rashmi
collection PubMed
description Breast cancer, in India, is the second commonest cancer in females. Receptor status with ER/PR/Her 2 is now routinely done in patients with invasive carcinoma. The tumour suppressor gene, p53, is also present in most breast cancers. Proteins produced by a mutated p53 gene, accumulate in the nucleus of tumour cells and are detected by immunohistochemistry (IHC). We have undertaken this study with the aim to evaluate the ER, PR, HER-2 and p53 expressions in invasive breast carcinomas by IHC and to compare the HER-2 expression with various clinicopathological parameters. MATERIALS AND METHODS: In this retrospective single institutional study from January 2001 to December 2010, 389 cases of histopathologically diagnosed infiltrating carcinoma of breast were evaluated taking into account various parameters like age, tumour size, grade, lymph node involvement, ER and PR. HER-2 and p53 was done in 352 cases. RESULTS: The age range was 23-90 years with a mean of 50.7 years. Majority of tumours were T2 (79.6%) and Grade II (60.9%). Our data showed overall 47.6% ER, 48.8% PR, 29.6% HER-2 and 69.2% p53 positivity. There was no significant correlation between HER-2 and age, tumour size, lymph node status, ER, and PR. There was significant correlation between HER-2 and tumour grade (P = 0.031), p53 (P < 0.001). There was no inverse correlation between HER-2 and combined ER, PR status. Triple-negative breast cancers which constituted 22.7% of our cases did not reveal any correlation with various parameters. CONCLUSION: In our study, ER status was low, and incidence of p53 was high. These findings suggest that many of the tumours in Indian females may be of an aggressive type, and novel treatment approaches may be tried. We conclude that the assessment of all four markers is desirable.
format Online
Article
Text
id pubmed-4477374
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-44773742015-07-08 Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience Patnayak, Rashmi Jena, Amitabh Rukmangadha, Nandyala Chowhan, Amit Kumar Sambasivaiah, K. Phaneendra, Bobbit Venkatesh Reddy, Mandyam Kumaraswamy Indian J Med Paediatr Oncol Original Article Breast cancer, in India, is the second commonest cancer in females. Receptor status with ER/PR/Her 2 is now routinely done in patients with invasive carcinoma. The tumour suppressor gene, p53, is also present in most breast cancers. Proteins produced by a mutated p53 gene, accumulate in the nucleus of tumour cells and are detected by immunohistochemistry (IHC). We have undertaken this study with the aim to evaluate the ER, PR, HER-2 and p53 expressions in invasive breast carcinomas by IHC and to compare the HER-2 expression with various clinicopathological parameters. MATERIALS AND METHODS: In this retrospective single institutional study from January 2001 to December 2010, 389 cases of histopathologically diagnosed infiltrating carcinoma of breast were evaluated taking into account various parameters like age, tumour size, grade, lymph node involvement, ER and PR. HER-2 and p53 was done in 352 cases. RESULTS: The age range was 23-90 years with a mean of 50.7 years. Majority of tumours were T2 (79.6%) and Grade II (60.9%). Our data showed overall 47.6% ER, 48.8% PR, 29.6% HER-2 and 69.2% p53 positivity. There was no significant correlation between HER-2 and age, tumour size, lymph node status, ER, and PR. There was significant correlation between HER-2 and tumour grade (P = 0.031), p53 (P < 0.001). There was no inverse correlation between HER-2 and combined ER, PR status. Triple-negative breast cancers which constituted 22.7% of our cases did not reveal any correlation with various parameters. CONCLUSION: In our study, ER status was low, and incidence of p53 was high. These findings suggest that many of the tumours in Indian females may be of an aggressive type, and novel treatment approaches may be tried. We conclude that the assessment of all four markers is desirable. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4477374/ /pubmed/26157289 http://dx.doi.org/10.4103/0971-5851.158844 Text en Copyright: © Indian Journal of Medical and Paediatric Oncology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Patnayak, Rashmi
Jena, Amitabh
Rukmangadha, Nandyala
Chowhan, Amit Kumar
Sambasivaiah, K.
Phaneendra, Bobbit Venkatesh
Reddy, Mandyam Kumaraswamy
Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience
title Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience
title_full Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience
title_fullStr Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience
title_full_unstemmed Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience
title_short Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience
title_sort hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in south indian breast cancer patients: a tertiary care center experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477374/
https://www.ncbi.nlm.nih.gov/pubmed/26157289
http://dx.doi.org/10.4103/0971-5851.158844
work_keys_str_mv AT patnayakrashmi hormonereceptorstatusestrogenreceptorprogesteronereceptorhumanepidermalgrowthfactor2andp53insouthindianbreastcancerpatientsatertiarycarecenterexperience
AT jenaamitabh hormonereceptorstatusestrogenreceptorprogesteronereceptorhumanepidermalgrowthfactor2andp53insouthindianbreastcancerpatientsatertiarycarecenterexperience
AT rukmangadhanandyala hormonereceptorstatusestrogenreceptorprogesteronereceptorhumanepidermalgrowthfactor2andp53insouthindianbreastcancerpatientsatertiarycarecenterexperience
AT chowhanamitkumar hormonereceptorstatusestrogenreceptorprogesteronereceptorhumanepidermalgrowthfactor2andp53insouthindianbreastcancerpatientsatertiarycarecenterexperience
AT sambasivaiahk hormonereceptorstatusestrogenreceptorprogesteronereceptorhumanepidermalgrowthfactor2andp53insouthindianbreastcancerpatientsatertiarycarecenterexperience
AT phaneendrabobbitvenkatesh hormonereceptorstatusestrogenreceptorprogesteronereceptorhumanepidermalgrowthfactor2andp53insouthindianbreastcancerpatientsatertiarycarecenterexperience
AT reddymandyamkumaraswamy hormonereceptorstatusestrogenreceptorprogesteronereceptorhumanepidermalgrowthfactor2andp53insouthindianbreastcancerpatientsatertiarycarecenterexperience